Brief: Lexicon Pharmaceuticals Announces Exclusive License Agreement With Novo Nordisk For LX9851
28/03/2025 11:49
March 28 (Reuters) - Lexicon Pharmaceuticals Inc LXRX.O: LEXICON PHARMACEUTICALS ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH NOVO NORDISK FOR LX9851 LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR UP TO $75 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS LEXICON PHARMACEUTICALS INC - ELIGIBLE FOR $1 BILLION IN TOTAL PAYMENTS LEXICON PHARMACEUTICALS INC - ENTITLED TO TIERED ROYALTIES ON NET SALES OF LX9851 LEXICON - NOVO NORDISK WILL BE RESPONSIBLE FOR FILING IND, ALL FURTHER DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF LX9851 Source text: ID:nGNX4hDsrs Further company coverage: LXRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lexicon Pharmaceuticals
See all newsLexicon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Lexicon Pharmaceuticals posts Q2 net loss
Brief: Lexicon Pharmaceuticals Q2 EPS USD -0.07
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview
Lexicon Pharmaceuticals Inc expected to post a loss of 5 cents a share - Earnings Preview